

## Sepsis

Condition for which IVIg is not supported.

### Specific Conditions

- Sepsis

### Level of Evidence

Evidence of probable benefit – more research needed (Category 2a)

### Adult and paediatric treatment or prevention

If immunoglobulin G (IgG) levels are low, the use of intravenous immunoglobulin (IVIg) should be considered under primary immunodeficiency diseases (PID) and/or secondary hypogammaglobulinaemia (including iatrogenic immunodeficiency).

### Neonatal prevention

IVIg is not supported. Therapy with IVIg had no effect on the outcomes of suspected or proven neonatal sepsis (Brockelhurst et al 2011).

## Bibliography

Alejandria Marissa, M, Lansang, M-AD, Dans Leonila, F & Mantaring, III JB 2002, 'Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock', *Cochrane Database of Systematic Reviews*, vol. 1, doi:10.1002/14651858. CD001090.

Brockelhurst, et al 2011, 'International Neonatal Immunotherapy Study (INIS) collaborative group. Treatment of neonatal sepsis with intravenous immune globulin', *New England Journal of Medicine*, vol. 365, pp. 1201–11.

Kreymann, KG, de Heer, G, Nierhaus, A & Kluge, S 2007, 'Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock', *Critical Care Medicine*, vol. 35, no. 12, pp. 2677–85.

Ohlsson, A & Lacy, J 2010, 'Intravenous immunoglobulin for suspected or subsequently proven infection in neonates', *Cochrane Database of Systematic Reviews*, doi:3CD001239.

Orange, JS, Hossny, EM, Weiler, CR, et al 2006, 'Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology', *Journal of Allergy and Clinical Immunology*, vol. 117, no. 4, pp. S525–53.

Generated on: 31 March 2019